Questcor to Host 2007 Fourth Quarter and Full Year Results Conference Call

Questcor Pharmaceuticals, Inc. (AMEX:QSC) announced today that it plans to report its financial results for the 2007 fourth quarter and full-year before the market opens on Tuesday, March 4, 2008 and host a conference call that will be conducted on the same day beginning at 11:00 a.m. ET. Don Bailey, President and Chief Executive Officer, George Stuart, Senior Vice President of Finance and Chief Financial Officer, and Steve Cartt, Executive Vice President, Corporate Development will host the call. To participate in the live call by telephone, please dial (800) 218-0530 from the U.S. or (303) 262-2130 from outside the U.S. Please use conference ID number 11108396#. Participants are asked to call the above numbers 5-10 minutes prior to the starting time. The call will also be webcast live at www.questcor.com. An audio replay of the call will be available for 7 days following the call at (800) 405-2236 for U.S. callers or (303) 590-3000 for those calling outside the U.S. The password required to access the replay is 11108396#. An archived webcast will also be available at www.questcor.com for 90 days. About Questcor - Questcor Pharmaceuticals, Inc. is a pharmaceutical company that owns two commercial products, H.P. Acthar® Gel ("Acthar”) and Doral® , and is developing new medications using strategies that generally require lower capital investment when compared to traditional development programs. Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS”). In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS”), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The Company is also developing new medications, including QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain. For more information, please visit www.questcor.com.